Uveitis associated with immune checkpoint inhibitors or BRAF/MEK inhibitors in patients with malignant melanoma
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Uveitis associated with immune checkpoint inhibitors or BRAF/MEK inhibitors in patients with malignant melanoma
Authors
Keywords
-
Journal
MELANOMA RESEARCH
Volume 33, Issue 6, Pages 539-546
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2023-10-04
DOI
10.1097/cmr.0000000000000933
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Characteristics of Ocular Inflammatory Side Effects Associated with Immune Checkpoint Inhibitors in a Northern California Population
- (2023) Ying Qian et al. OCULAR IMMUNOLOGY AND INFLAMMATION
- Case with metastatic cutaneous malignant melanoma that developed Vogt–Koyanagi–Harada-like uveitis following pembrolizumab treatment
- (2021) Hiroko Enomoto et al. DOCUMENTA OPHTHALMOLOGICA
- Classification criteria for Vogt-Koyanagi-Harada Disease
- (2021) Douglas A. Jabs et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- A case of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib/trametinib therapy for advanced melanoma
- (2020) Maria Brambati et al. EUROPEAN JOURNAL OF OPHTHALMOLOGY
- Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes
- (2020) Eliot R. Dow et al. OCULAR IMMUNOLOGY AND INFLAMMATION
- Immune Checkpoint Inhibitor-Induced Uveitis
- (2020) Emmett T. Cunningham et al. OCULAR IMMUNOLOGY AND INFLAMMATION
- The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma
- (2020) Florentia Dimitriou et al. EUROPEAN JOURNAL OF CANCER
- OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS
- (2019) Silvia Méndez-Martínez et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series
- (2019) Jenna May Kim et al. OPHTHALMOLOGY
- Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition
- (2019) Michel M. Sun et al. OCULAR IMMUNOLOGY AND INFLAMMATION
- Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
- (2019) John A. Thompson et al. Journal of the National Comprehensive Cancer Network
- Prevalence and clinical patterns of ocular complications associated with anti-PD-1/PD-L1 anticancer immunotherapy
- (2019) Karen Bitton et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review
- (2019) Shaheen Khan et al. SEMINARS IN CANCER BIOLOGY
- Bilateral ipilimumab-induced posterior uveitis following treatment for metastatic choroidal melanoma
- (2018) Alexander XJ Tan et al. CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care
- (2018) Emily Z. Keung et al. Expert Review of Anticancer Therapy
- Long-Term Outcomes in Patients With BRAF V600–Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib
- (2018) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy
- (2018) Taku Fujimura et al. JOURNAL OF DERMATOLOGY
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- CHECKPOINT INHIBITOR IMMUNE THERAPY
- (2018) Lauren A. Dalvin et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review
- (2017) Omar Abdel-Rahman et al. Expert Review of Anticancer Therapy
- Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis
- (2017) James Larkin et al. ONCOLOGIST
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient
- (2016) Takashi Arai et al. JOURNAL OF DERMATOLOGY
- Risk of Ophthalmic Adverse Effects in Patients Treated with MEK Inhibitors: A Systematic Review and Meta-Analysis
- (2016) Carlos Alves et al. OPHTHALMIC RESEARCH
- Vogt-Koyanagi-Harada-like Syndrome After CTLA-4 Inhibition With Ipilimumab for Metastatic Melanoma
- (2015) Jason N. Crosson et al. JOURNAL OF IMMUNOTHERAPY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
- (2015) Sarah J. Welsh et al. Therapeutic Advances in Medical Oncology
- Ocular Toxicity in BRAF Mutant Cutaneous Melanoma Patients Treated With Vemurafenib
- (2014) Christina H. Choe et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of HLA-DR4/HLA-DRB1*04 with Vogt-Koyanagi-Harada disease: A Systematic Review and Meta-analysis
- (2014) Tingkun Shi et al. Scientific Reports
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vogt-Koyanagi-Harada Syndrome
- (2009) Wang Fang et al. CURRENT EYE RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started